Jan 3 (Reuters) - CVS Health CVS.N said on Wednesday it will remove AbbVie’s ABBV.N blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of April ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min CVS will remove Abbvie's Humira ...
(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...
MedImpact Healthcare Systems, an independent provider of health solutions, technology and pharmacy benefit services, is expanding access to Humira biosimilars, Simlandi and adalimumab-adaz, for new ...
A year ago, Blue Shield of California announced that it would move on from a traditional pharmacy benefit management relationship with CVS' Caremark and instead adopt a new model that leans on ...
The Food and Drug Administration has accepted for review an application from Amgen for a biosimilar drug to compete with AbbieVie Inc.’s Humira. Amgen in Thousand Oaks calls its drug ABP 501. Humira ...
The Food and Drug Administration has granted an expanded interchangeable designation for Celltrion’s Yuflyma (adalimumab-aaty), now including prefilled syringe (40mg) and autoinjectors (40mg and 80mg) ...
CVS also announced that AbbVie and CVS-owned company Cordavis, which launched in August, will produce a co-branded version of Humira that will be made available to customers in the second quarter of ...
(Reuters) - UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results